Stock Analysis
ImmunityBio, Inc. (IBRX) Stock Analysis
ImmunityBio, Inc. (IBRX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
ImmunityBio, Inc. (IBRX) currently has an AIQ Score of 56/100, indicating a neutral setup. Quality is the strongest factor at 100/100. Risk is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
IBRX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $8.29 |
| AIQ Score | 56/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Neutral |
| Market Cap | $8.24B |
| P/E Ratio (TTM) | -8.08 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | -$0.22 |
| Revenue (quarter ended 2026-06-30) | $51.24M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.13 |
| Volume | 8.96M |
| 52-week range | $1.95-$12.43 |
| RSI 14 | 31.83 |
| 50-Day SMA | $8.70 |
| 200-Day SMA | $7.88 |
| Analyst Price Target | $14.00 |
| Next Earnings | Nov 3, 2026 |
IBRXImmunityBio, Inc.
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum46
- Value34
- Quality100
- Risk resilience28
- Sentiment—
IBRX Stock Analysis Summary
ImmunityBio, Inc. (IBRX) currently has an AIQ Score of 56/100, indicating a neutral setup. Quality is the strongest factor at 100/100. Risk resilience is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, IBRX has AIQ Score of 56/100 with Quality base of 100/100 and fading Risk resilience at 28/100. Wait for component alignment before adding exposure.
Quality (100/100) leads while Risk resilience (28/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -5.15% stock move · IBRX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is IBRX Bullish or Bearish Right Now?
IBRX currently has a neutral overall setup. Quality is the strongest factor at 100/100, while Risk Resilience is weakest at 28/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 100/100.
- - Price is +0.49% above its 50-day SMA.
- - Analyst target implies +68.88% upside from the latest quote.
- - Value is the current constraint at 34/100.
- - Risk Resilience is weak at 28/100.
- - Technical consensus has more sell votes than buy votes (22 vs 16).
Current Consensus
IBRX's Technical Analysis Consensus is currently Neutral, with 16 buy, 7 neutral, and 22 sell votes. IBRX's 14-day RSI is 31.83, which places the stock in a weaker momentum range. IBRX's beta is 0.13, indicating lower market sensitivity than the broad market.
What Changed in IBRX?
The largest recent change in IBRX is Momentum moving up by 15.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the IBRX Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
IBRX Decision Framework
Public evidence layers, setup checks, and risk context for ImmunityBio, Inc..
ImmunityBio, Inc. (IBRX) Stock Analysis
ImmunityBio, Inc. has an AIQ Score of 56/100 in a Neutral regime. Quality is strongest at 100/100. Beta is 0.13, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | IBRX is in a Neutral AIQ regime with score 56/100. |
| Signal Conflict | The primary conflict is that quality leads at 100/100 while risk lags at 28/100. |
| Factor Evidence | Momentum 46/100 · Value 34/100 · Quality 100/100 · Risk 28/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 100/100.
Momentum is 46/100 and RSI (14) is 31.8.
IBRX is in a Neutral regime at 56/100.
Risk factor is 28/100 with beta 0.13 and annual volatility 106.96%.
Current conflict: quality leads at 100/100 while risk lags at 28/100.
IBRX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
IBRX Fundamentals
IBRX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
IBRX Technical Analysis
IBRX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
IBRX Stock Catalysts
Track IBRX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
IBRX Dividend Analysis
IBRX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
IBRX Financial Data
IBRX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
IBRX Risk Analysis
IBRX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
IBRX Stock News
IBRX stock news, market tone, recent headlines, and catalyst context.
IBRX vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: IBRX · ICLR · IONS · IOVA · ITCI. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| IBRX Current stock | 56/100 | 34/100 | 46/100 | 28/100 | 1.67 | 106.96% | Current |
| ICLR ICON | 61/100 | 67/100 | 93/100 | 41/100 | 0.71 | 68.63% | IBRX vs ICLR |
| IONS Ionis Pharmaceuticals | 36/100 | 34/100 | 41/100 | 42/100 | -1 | 42.61% | IBRX vs IONS |
| IOVA Iovance Biotherapeutics | 35/100 | 34/100 | 30/100 | 53/100 | 1.92 | 110.75% | IBRX vs IOVA |
| ITCI Intra-Cellular Therapies | 54/100 | 34/100 | — | 82/100 | — | — | IBRX vs ITCI |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching IBRX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for IBRX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
IBRX Stock FAQ
What is IBRX stock price today?
ImmunityBio, Inc.'s current stock price is $8.29. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is IBRX bullish or bearish right now?
IBRX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is IBRX's market cap?
IBRX's market cap is $8.24B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is IBRX's current P/E ratio?
IBRX's current P/E ratio is -8.08 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is IBRX's RSI?
IBRX's 14-day RSI is 31.83 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is IBRX above its 50-day and 200-day moving averages?
IBRX is 0.49% from its 50-day SMA and 10.97% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is IBRX's next earnings date?
IBRX's next earnings date is currently listed as Nov 3, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does IBRX pay a dividend?
IBRX's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.